The cardiovascular safety of tadalafil

Expert Opinion on Drug Safety

Volumn 7, Issue 1, 2008, Pages 43-52

  Reffelmann, Thorsten ^a,b   Kieback, Arne ^a   Kloner, Robert A ^b  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Erectile dysfunction; Heart disease; Hypertension; Nitrates; Phosphodiesterase 5; Tadalafil

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANALGESIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DOBUTAMINE; DOXAZOSIN; ENALAPRIL; GLYCERYL TRINITRATE; IBUTILIDE; METOPROLOL; NITRATE; NITRIC OXIDE DONOR; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; TAMSULOSIN; TERAZOSIN; THIAZIDE DIURETIC AGENT; VARDENAFIL;

ANGINA PECTORIS; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL PRESSURE; ARTERY STEAL SYNDROME; BACKACHE; BLEEDING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BLOOD FLOW; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HEART ARRHYTHMIA; HEART DEATH; HEART ELECTROPHYSIOLOGY; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEART RIGHT LEFT SHUNT; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; LIMB PAIN; MYALGIA; NONHUMAN; NOSE CONGESTION; PROSTATE HYPERTROPHY; PROTEIN LOCALIZATION; PROTEIN TARGETING; PULMONARY HYPERTENSION; QT PROLONGATION; REVIEW; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; SYNCOPE; TACHYCARDIA; VASODILATATION;

ANIMALS; CARBOLINES; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS AS TOPIC; ERECTILE DYSFUNCTION; HUMANS; MALE;

EID: 38949188913     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.1.43     Document Type: Review

References (74)

1. Carson CC, Rajfer J, Eardley S, et al. The efficacy and safety of tadalafil: an update. BJU Int 2004;93:1276-81
2. Lewis RL, Sadovsky R, Eardley I, et al. The efficacy of tadalafil in clinical populations. J Sex Med 2005;2:517-31
3. Montorsi F, Padma-Nathan H, Mccullough A, et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo-controlled trial. J Urol 2004;72:1036-41
4. McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005;2:415-24
5. Mirone V, Costa P, Damber JE, et al. An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. Eur Urol 2005;47:846-54
6. Levine LA. Diagnosis and treatment of erectile dysfunction. Am J Med 2000;109:S3-S12
7. Nusbaum MR. Erectile dysfunction: prevalence, etiology, and major risk factors. J Am Osteopath Assoc 2002;102:S1-S6
8. Reffelmann T, Kloner RA. Sexual function in hypertensive patients receiving treatment. Vasc Health Risk Manag 2006;2:447-55
9. Laumann EO, West S, Glasser D, et al. Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: from the male attitudes regarding sexual health survey. J Sex Med 2007;4:57-65
10. Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 2000;12:305-11
11. Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 2000;163:460-3
12. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61
13. Viraq R, Bouillo P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet 1985;1:181-4
14. O'Kane PD, Jackson G. Erectile dysfunction: is there silent obstructive coronary artery disease? Int J Clin Pract 2001;55:219-20
15. Walczak MK, Lokhandwala N, Hodge MB, et al. Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med 2002;6:19-21
16. Gazzaruso C, Giordanetti S, De Amici E., et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 2004;110:22-6
17. Thompson IM, Tangen CM, Goodman PJ, et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005;294:2996-3002
18. Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005;96:313-21
19. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 2003;89:251-3
20. Kaiser DR, Billups K, Mason C, et al. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004;43:179-84
21. Reffelmann T, Kloner RA. Therapeutic potential of phosphadiesterase 5 inhibition for cardiovascular disease. Circulation 2003;108:239-44
22. Reffelmann T, Kloner RA. Phamacotherapy of erectile dysfunction: focus on cardiovascular safety. Expert Opin Drug Saf 2005;4:531-40
23. Debusk R, Dory Y, Goldstein I, et al. Management of sexual dysfunction in patients with cadiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol 2000;86:175-81
24. Cheitlin MD, Hutteram, Kennedy JW, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol 1999;33:273-82
25. Muller JE. Sexual activity as a trigger for cardiovascular events: what is the risk? Am J Cardiol 1999;84:N2-N5
26. Drory Y, Shapita I, Fisman EZ, et al. Myocardial ischemia during sexual activity in patients with coronary artery disease. Am J Cardiol 1995;75:835-7
27. Muller JE, Mittleman MA, Maclure M, et al. Triggering myocardial infarction by sexual activity: low absolute risk and prevention by regular physical exercise. JAMA 1996;275:1405-9
28. Ueno M. The so-called coition death. Jpn J Leg Med 1963;17:330-5
29. Bravo JA. Cyclic nucleoside phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995;75:725-48
30. Wallis RM, Corbin JD, Francis SH, et al. Tissue distribution of phosphodiesterase families and the effect of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999;83:C3-C12
31. Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitor sildenafil, vardenafil and tadalafil: review of the literature. Eur J Med Res 2002;7:435-46
32. Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2004;44:1488-96
33. Przyklenk K, Kloner RA. Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis. J Am Coll Cardiol 2001;37:286-92
34. Senzaki H, Smith CJ, Juang GJ, et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates β-adrenergic signaling in vivo and is downregulared in heart failure. FASEB J 2001;15:1718-26
35. Takimoto E, Belardi E, Toccetti CG, et al. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5. Circulation 2007;115:2159-67
36. Castro LR, Verde I, Cooper DM, Fischmeister R. Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation 2006;113:2221-8
37. Sesti C, Florio V, Johnson EG, Kloner RA. The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size, Int J Impot Res 2007;19:226-7
38. Kukreja RC, Ockaili R, Salloum F, et al. Cardioprotection with phosphdiesterase-5 inhibition - a novel preconditioning strategy. J Mol Cell Cardiol 2004;36:165-73
39. Nagendran J, Archer SL, Solinian D, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007;116:233-5
40. Katz SD, Balidemaj K, Homma S, et al. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000;36:845-51
41. Bocchi EA, Guimaraes G, Mocelin A, et al. Sildenafil effects on exercise, neurohumoral activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002;106:1097-103
42. Halcox JPJ, Nour KRA, Zalos G, et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002;40:1232-40
43. Eli Lilly and Company. Cialis® (tadalafil) tablets, product information. Eli Lilly and Company, Indianapolis, (IN) USA; 2007
44. Emmick JT, Stuewe SR, Mitchell M. Overview of the cardiovascular effects of tadalafil. Eur Heart J 2002;4(Suppl H):H32-H37
45. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol 2003;92(Suppl):M37-M46
46. Pattterson D, Mcinnes GT, Webster J, et al. Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension. Br J Clin Pharmacol 2006;62:280-7
47. Kloner RA, Hutter AH, Emmick JT, et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003;42:1855-60
48. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 2003;92:M47-M57
49. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004;110:3149-55
50. Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phosphodiesterase 5 inhibitor tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004;172:1935-40
51. Herrmann HC, Chang G, Klugherz B, et al. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000;342:1622-6
52. Arruda-Olson AM, Mahoney DW, Nehra A, et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease. JAMA 2002;287:719-25
53. Thadani U, Smith W, Nash S, et al. The effect of vardenafil, a potent and highly selective phosphodiesterase 5 inhibitor for the treatment of erecti]e dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002;40:2006-12
54. Patterson D, Kloner R, Emmick J, et al. The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. Br J Clin Pharmacol 2005;60:459-68
55. Weinsaft JW, Hickey K, Bokhari S, et al. Effects of tadalafil on myocardial blood flow in patients with coronary artery disease. Coron Artery Dis 2006;17:493-9
56. Rosano GMC, Aversa A, Vitale C, et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005;47:111-214
57. Bocchio M, Pelliccione F, Passaquale G, et al. Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction. Atherosclerosis 2006; In Press
58. Aversa A, Greco E, Bruzziches R, et al. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Import Res 2007;19:200-7
59. Beasley CM, Mitchell MI, Dmitrienko AA, et al. The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. J Am Coll Cardiol 2005;46:678-87
60. Jackson G, Kloner RA, Costigan TM, em al. Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. J Sex Med 2004;1:161-7
61. Swissa M, Ohara T, Lee MH, et al. Sildenafil-nitric oxide donor combination promotes ventricular tachyarrhythmia in the swine right ventricle. Am J Physiol 2002;282:H1787-92
62. Geelen P, Drolet B, Rail J, et al. Sildenafil cstrate (Viagra) prolongs cardiac repolarisation by blocking the rapid component of the delayed rectifier potassium current. Circulation 2000;102:275-7
63. Reffelmann T, Kloner RA. Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation. Cardiovasc Res 2003;59:441-9
64. Feenstra J, Van Drie-Pierik RJ, Lacle CF, et al. Acute myocardial infarction associated with sildenafil. Lancet 1998;352:957-8
65. Wysowski DK, Farinas E, Swartz L. Comparison of reported and expected deaths in sildenafil (Viagra) users. Am J Cardiol 2002;89:1331-4
66. Kloner RA, Jackson G, Hutter AM, et al. Cardiovascular safety update of tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of tadalafil with as needed, three times-per-weekor once-a-day dosing. Am J Cardiol 2006;97:1778-84
67. Eardley I, Gentile V, Austoni E, et al. Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction. BJU Int 2004;94:871-7
68. Brock H, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil far the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002;168:1332-6
69. Goldstein I, Kim E, Steers WD, et al Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US. J Sex Med 2007;4:166-75
70. Morgentaler A, Barada J, Noederberger C, et al. Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: use of a novel noninferiority study design. J Sex Med 2006;3:492-503
71. Hazell L, Boshier A, Harris S, Wilton LV, Shakir SA. An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care England: mortality due to ischaemic heart disease. BJU Int 2007;99:387-93
72. Mittleman MA, Maclure M, Tofler GH, et al. Triggering of acute myocardial infarction by heavy physical exertion - protection against triggering by regular exertion. N Engl J Med 1993;329:1677-83
73. Bohlen JG, Held JP, Sanderson MO, et al. Heart rate and blood pressure response to four sexual activities. Arch Int Med 1984;144:1745-8
74. Larson JL, Mcnaughton MW, Kennedy JW, et al. Heart rate and blood pressure response to sexual activity and a stair climbing test. Heart Lung 1980;9:1025-30